Logo – ‘The acquisition of Oculeve further enhances Allergan's world-class position in eye care and underscores our dedication to continuing to build up a broad range of treatment plans for patients with eyes conditions,’ said Brent Saunders, CEO and President of Allergan. ‘Dry eyes is currently an underserved condition, with many individuals not receiving sufficient treatment from over-the-counter choices. Allergan is focused on expanding our item offerings in this category, and the development of OD-01, an intranasal neurostimulation device, is complementary to our market-leading dry vision treatment, Restasis®, as well as other dry eye items in development in your pipeline.’ The acquisition of Oculeve provides novel, complementary dried out eye development programs to Allergan's current eye care research and development programs, including OD-01, a noninvasive nasal neurostimulation gadget that increases tear production in patients with dry attention disease.Cheifetz for The Advancement of VKASS: A Digital Knee Anatomy and Surgery System $40,000 to Frank Krueger , Roberty Lipsky , Kevin A. McCabe for Variation at the Oxytocin Receptor Gene Influences Responsivity of Neural Circuitry for Interpersonal Trust: Developing Molecular Markers for Neuropsychiatric Disorders $40,000 to Monique van Hoek and Shahzad Ahmad for Antimicrobial Peptides in Idiopathic Pulmonary Fibrosis $20,000 to Siddhatha Sikdar , Margaret Griffen , Anne Rizzo , Tayseer Aldaghlas , Christopher Michetti , Urszula Bartlett and Linda Robinson for Novel Methods for Sonographic Evaluation of Blunt Cervical Vascular Accidents $20,000 to Y. Tony Yang and Linda Henry for The Perioperative Nurse’s Role in Mistake Recovery: From Assessing Characteristics of Near Mistakes to Developing Interventions for Improving the Quality of Surgical Treatment $10,000 to Randall E.